SCHEMBL26048876

SCHEMBL26048876

COC(=O)c1ccc(C)c(OCCO)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.55
L3MBTL1 Q9Y468 3/20 0.54
TDP1 Q9NUW8 2/20 0.54
NOTUM Q6P988 1/20 0.54
MAPT P10636 6/20 0.47
LMNA P02545 2/20 0.47
GAA P10253 1/20 0.47
TTR P02766 1/20 0.45
CYP4A11 Q02928 4/20 0.45
CYP4F2 P78329 3/20 0.45
TSHR P16473 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
XDH P47989 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
RAB9A P51151 3/20 0.44
KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17991551 0.88 TDP1 (0.54) ALDH1A1L3MBTL1TDP1NOTUMMAPT
SCHEMBL12492829 0.88 ALDH1A1 (0.55) ALDH1A1L3MBTL1TDP1NOTUMMAPT
SCHEMBL17129602 0.88 L3MBTL1 (0.57) ALDH1A1L3MBTL1TDP1NOTUMMAPT
SCHEMBL2934574 0.86 TDP1 (0.52) ALDH1A1L3MBTL1TDP1NOTUMMAPT
SCHEMBL9478194 0.86 L3MBTL1 (0.56) ALDH1A1L3MBTL1TDP1NOTUMMAPT
SCHEMBL17991550 0.86 NOTUM (0.59) ALDH1A1L3MBTL1TDP1NOTUMMAPT
SCHEMBL15574247 0.84 MAPT (0.62) ALDH1A1MAPTLMNAGAATSHR
SCHEMBL8398812 0.84 KDM4E (0.53) ALDH1A1L3MBTL1TDP1MAPTLMNA
SCHEMBL18031268 0.84 MAPT (0.62) MAPTLMNATSHRCA12CA1
SCHEMBL31401228 0.84 TSHR (0.51) ALDH1A1TDP1TTRTSHRCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Apollo Therapeutics Limited (GB) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 ALDH1A1 2913/4885L3MBTL1 3250/4885TDP1 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.